On this page
Back to topMaze Therapeutics MAZE
Maze Therapeutics listed on Nasdaq on 31 Jan 2025 and is not in the S&P 500. It is worth $1.8 billion. Its board has 12 directors, 6 of them independent. 5 other officers are on file. At 30 Jun 2026, Frazier Life Sciences Management was its largest institutional holder, with 9.1% of the company.
- Chair
- Herve Hoppenot
- Listed
- 31 Jan 2025 on Nasdaq
- Headquarters
- South San Francisco, CA
- Market cap
- $1.8B
- 19 Nov 2026 close
- Price to sales
- 10.6
- On fiscal 2024 revenue
Financials
Financial history
Twelve months to 31 Mar 2026, from Maze Therapeutics' quarterly filings.
Quarters since Jun 2024
- P/E
- -
- No profit over the last four quarters
Quarterly results
Each quarter's revenue, net income and free cash flow.
Jun 2024 to Mar 2026
Not reported for enough quarters.
Not reported for enough quarters.
Not reported for enough quarters.
| Quarter | Revenue | Net income |
|---|---|---|
| Mar 2026 | $20M | $-24M |
| Sep 2024 | $3M | $-25M |
| Jun 2024 | $165M | $139M |
Maze Therapeutics' market cap since January 2025
Marked weeks are changes in the share count, such as a merger, not market moves.
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $1.9B |
| 26 Dec 2025 | $2.0B |
Download Maze Therapeutics' data as JSON, with the weekly market caps in billions of dollars from 31 Jan 2025.
Board and leadership
Board and officers
2 people here also hold roles at other S&P 500 companies.
Board from the proxy filed 28 Apr 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (12) | |||||
| Herve HoppenotChairIndependent 路 since 2025 路 AuditFormer Chief Executive Officer, Incyte CorporationOther boards: Incyte and Bicycle Therapeutics | |||||
| Nancy C. AndrewsDirectorAlso at Charles River Laboratories | |||||
| Nancy C. Andrews, M.D., Ph.D.DirectorIndependent 路 since 2021 路 Compensation, Research and DevelopmentExecutive Vice President and Chief Scientific Officer, Boston Children's HospitalOther boards: Novartis and Charles River Laboratories | |||||
| Jason Coloma, Ph.D.Director and CEONot independent 路 since 2019 | |||||
| Charles J. HomcyDirectorNot independent 路 since 2018 路 Nominating and Corporate Governance, Research and DevelopmentCo-founder, Maze Therapeutics, Inc. and BridgeBio Pharma, Inc.Other boards: BridgeBio Pharma | |||||
| Paula A. JohnsonDirectorAlso at Johnson & Johnson | |||||
| Sophie KornowskiDirector | |||||
| Neil Kumar, Ph.D.DirectorIndependent 路 since 2026Chief Executive Officer, BridgeBio Pharma, Inc.Other boards: BridgeBio Pharma, Eidos Therapeutics, BridgeBio Oncology Therapeutics and LianBio | |||||
| Jonathan E. LimDirectorIndependent 路 since 2019 路 Compensation (chair)Chairman and Chief Executive Officer, Erasca, Inc.; Venture Partner, ARCH Venture Partners, LLCOther boards: Erasca and Boundless Bio | |||||
| Richard H. SchellerDirector | |||||
| Richard Scheller, Ph.D.DirectorIndependent 路 since 2019 路 Research and Development (chair)Chair of Research and Development, BridgeBio Pharma Inc.Other boards: 23andMe and Alector | |||||
| Daniel K. SpiegelmanDirectorIndependent 路 since 2020 路 Audit (chair), Nominating and Corporate GovernanceCorporate Director; Former Executive Vice President and Chief Financial Officer, Biomarin Pharmaceuticals Inc.Other boards: Spruce Biosciences, Kyverna Therapeutics and vTv Therapeutics | |||||
| Officers (5) | |||||
| Misbah TahirChief Financial OfficerLast filed 3 Mar 2026 | |||||
| Harold BernsteinPresident, R&D & CMOLast filed 8 Sep 2026 | |||||
| Jason V. ColomaChief Executive OfficerLast filed 4 Sep 2026 | |||||
| Phillips CourtneyGC and Corp. SecretaryLast filed 4 Sep 2026 | |||||
| Atul DandekarCsboLast filed 4 Sep 2026 | |||||
Owners and trading
Largest institutional holders
Each fund group's share of Maze Therapeutics. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers sold $25.0 million of stock in 55 sales and made no open-market purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 2 Nov 2026Sale | Jason V. ColomaChief Executive Officer | $1.0M |
| 29 Oct 2026Sale | Atul DandekarCsbo | $241K |
| 1 Oct 2026Sale | Jason V. ColomaChief Executive Officer | $932K |
| 1 Oct 2026Sale | Harold BernsteinPresident, R&D & CMO | $435K |
| 29 Sep 2026Sale | Atul DandekarCsbo | $203K |
| 4 Sep 2026Sale | Harold BernsteinPresident, R&D & CMO | $254K |
| 3 Sep 2026Sale | Jason V. ColomaChief Executive Officer | $297K |
| 3 Sep 2026Sale | Harold BernsteinPresident, R&D & CMO | $135K |
| 3 Sep 2026Sale | Atul DandekarCsbo | $84K |
| 3 Sep 2026Sale | Phillips CourtneyGC and Corp. Secretary | $52K |
Showing 10 of 55 trades
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
4 departures and 7 appointments of directors and officers and 7 large insider sales in the last two years.
Insider sales of $1 million or more, and the largest tenth of Maze Therapeutics' insider sales.
Events, newest first
- 2 Nov 2026 Jason V. Coloma sold $1.0MChief Executive Officer
- 13 Aug 2026 Herv茅 Hoppenot resignedClass II director
- 13 Aug 2026 Nancy C. Andrews resignedClass III director
- 13 Aug 2026 Herv茅 Hoppenot appointedClass III director
- 13 Aug 2026 Nancy C. Andrews appointedClass II director
- 13 Aug 2026 Sophie Kornowski appointedClass I director
- 13 Aug 2026 Paula A. Johnson appointedClass III director
- 1 Jul 2026 Jason V. Coloma sold $1.0MChief Executive Officer
Showing 8 of 18 events
| Date | Event | Filing |
|---|---|---|
| 2 Nov 2026 | Jason V. Coloma sold $1.0MChief Executive Officer | Form 4 |
| 13 Aug 2026 | Herv茅 Hoppenot resignedClass II director | 8-K |
| 13 Aug 2026 | Nancy C. Andrews resignedClass III director | 8-K |
| 13 Aug 2026 | Herv茅 Hoppenot appointedClass III director | 8-K |
| 13 Aug 2026 | Nancy C. Andrews appointedClass II director | 8-K |
| 13 Aug 2026 | Sophie Kornowski appointedClass I director | 8-K |
| 13 Aug 2026 | Paula A. Johnson appointedClass III director | 8-K |
| 1 Jul 2026 | Jason V. Coloma sold $1.0MChief Executive Officer | Form 4 |
| 18 May 2026 | Amy Bachrodt resignedSenior Vice President, Finance, effective 1 Jun 2026 | 8-K |
| 24 Mar 2026 | Neil Kumar appointedClass I director, effective 27 Mar 2026 | 8-K |
| 10 Mar 2026 | Harold Bernstein sold $1.5MPresident, R&D & CMO | Form 4 |
| 7 Jan 2026 | Catherine A. Sohn sold $1.1MDirector | Form 4 |
| 7 Jan 2026 | Harold Bernstein sold $1.0MPresident, R&D & CMO | Form 4 |
| 29 Dec 2025 | Atul Dandekar sold $2.9MCsbo | Form 4 |
| 29 Dec 2025 | Harold Bernstein sold $1.8MPresident, R&D & CMO | Form 4 |
| 6 Oct 2025 | Charles Homcy leftChairman of the Board | 8-K |
| 6 Oct 2025 | Herv茅 Hoppenot appointedClass II director and as the Chairman of the Board | 8-K |
| 2 Sep 2025 | Misbah Tahir appointedChief Financial Officer | 8-K |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.